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Abstract It is well known that the number of patients requir-
ing a vascular grafts for use as vessel replacement in cardio-
vascular diseases, or as vascular access site for hemodialysis is
ever increasing. The development of tissue engineered blood
vessels (TEBV’s) is a promising method to meet this increas-
ing demand vascular grafts, without having to rely on poorly
performing synthetic options such as polytetrafluoroethylene
(PTFE) or Dacron. The generation of in vivo TEBV’s in-
volves utilizing the host reaction to an implanted biomaterial
for the generation of completely autologous tissues.
Essentially this approach to the development of TEBV’s
makes use of the foreign body response to biomaterials for
the construction of the entire vascular replacement tissue with-
in the patient’s own body. In this review we will discuss the
method of developing in vivo TEBV’s, and debate the ap-
proaches of several research groups that have implemented
this method.
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Introduction
Globally there is an immense and ever increasing need for
vascular grafts for use as vessel replacement in cardiovascular
diseases (CVD), or as vascular access site for hemodialysis. It
is widely known that the incidence of CVD is increasing, a
trend expected to continue in the foreseeable future [1, 2]. This
coincides with an increase in the number of end-stage renal
disease (ESRD) patients requiring a vascular access (VA) site
[3]. Ideally, autologous veins or arteries are used as grafts, as
these are associated with superior patency [4, 5]. However,
due to a relative lack of donors, previous harvesting, or the
poor state of the patients own vessels, native arteries and veins
are not available for grafting in a substantial portion of pa-
tients. In such cases prosthetic grafts offer a suitable alterna-
tive and are frequently utilized. However, the primary patency
for these synthetic grafts is dismal, both as arterial bypass, and
arteriovenous graft for hemodialysis [6]. This failure of syn-
thetic vascular grafts is primarily due to intimal hyperplasia,
thrombosis and infection [7, 8].
Tissue engineered blood vessels (TEBV’s) may be a prom-
ising alternative for patients requiring a vessel replacement or
VA site. Numerous approaches to the development of tissue
engineered grafts have been described, and extensively
reviewed [9–11]. The majority of these approaches tend to
involve complex in vitro preparation steps, decellularized con-
structs, or the incorporation of synthetic materials onto the
TEBV. Ideally, a vascular replacement is made completely
out of cellularized autologous tissue, thereby not causing
any immune reaction, and retaining the ability to remodel
in vivo.
In the present review, we will discuss approaches that uti-
lize the host reaction to an implanted biomaterial for the
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generation of completely autologous TEBV’s in vivo. In other
words, this approach to regenerative medicine and the devel-
opment of TEBV’s aims to make use of the body’s foreign
body response to biomaterials, and exploit the host environ-
ment as a bioreactor for the generation of new tissues, essen-
tially allowing for the construction of the entire vascular graft
within the patient’s body. Interestingly, most biomedical re-
search concerning the foreign body response (FBR) is con-
ducted with the aim of minimizing, or abolishing the cascade
resulting in this host reaction, as propagation of the FBR is
commonly associated with a decrease in implant functionality
[12, 13 ]. Yet, by utilizing the FBR to generate tissue constructs
in a controlled setting, various groups have developed
methods to construct TEBV’s [14–17]. This involves an im-
plantable biomaterial, which elicits a FBR to allow the growth
of tissue around it (Figure 1.). TEBV’s made in this way
would be non-toxic, elicit no immune response, and be free
of pre-existing disease as the tissue is completely autologous,
none of the initial foreign material remains in the body to
propagate an immune response [18].
There are several requirements to which a TEBV’s must
adhere in order to be considered as a promising vessel substi-
tute. These factors must be taken into account when through
the developing a TEBV. An overview of the requirements of
TEBV’s is provided in Table 1.
The concept of using the host as an in vivo bioreactor is not
new. Already in 1961, Schillings et al. attempted to make
autologous grafts by implanting stainless steel mesh cylinders
subcutaneously for 4 months in 12 dogs. Five of these grafts
failed due to thrombosis, technical errors and bleeding.
However, the remaining 7 grafts showed an impressive paten-
cy of 3 years. Yet, it was Sparks who truly pioneered the
application of autologous capsulated tissue as vascular grafts
grown in vivo in the 1960’s, with the grafts being briefly
applied in clinical applications [20, 21]. Dacron fabric grafts,
covered by layers of fibrous tissue that formed as a result of
the subcutaneous implantation of silicone rods, were clinically
implemented as arterial bypass grafts in the late 1960’s.
However, the application of this TEBV approach was report-
edly low, as follow-up studies showed that there were various
complications concerning the technique [22–25]. A main is-
sue was the long incubation time that was required for the
formation of the tissue around the implant, although this did
not always yield a suitable graft. Thrombosis and stenotic
occlusion of the graft was the main reason for late graft failure,
while 20% of the grafts experienced aneurysm formation [23].
Little information is available on the mechanical properties of
the Spark’s graft, which could give an indication of why an-
eurysm formation occurred. However, it is likely that a main
downside of the Spark’s graft is the lack of sufficient
Fig. 1 An overview of the in vivo based concept. I) a biomaterial is
implanted in the host. II) The host environment acts as a bioreactor,
leading to the encapsulation of the biomaterial with a cellularized
fibrous tissue capsule. III) The implant device is removed, leaving only
the tissue capsule. IV) The tissue capsule is grafted to the vasculature,
creating a TEBV. V) Over time remodeling occurs, where the TEBV
transdifferentiates to attain characteristics of a native blood vessel
Table 1 An overview of the requirements of a TEBV
I) the mechanical properties of the vessel must be sufficient to withstand
the pressure caused by flow for extended periods of time without
resulting in an aneurysm or bursting;
II) the vessel should be sufficiently compliant to avoid a compliance
mismatch, a known factor for graft failure [19];
III) the surgical suitability must be considered; the graft must have
sufficient suture retention strength, and be easy to handle by the
surgeon;
IV) the vessel must be compatible with the host, i.e. not elicit an
inflammatory reaction, be non-toxic, and non-carcinogenic;
V) the vessel should be capable of remodeling to meet the demands of the
vasculature;
VI) the surface of the graft should not be prone to thrombus formation.
VII) be produced in a large scale, cost effective manner, and available in
various dimensions;
VIII) show acceptable variation between batches.
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mechanical properties (concluded by the high rate of aneu-
rysm formation). Incorporation of the polymer into the tissue
and the low cell density of the graft may be one of the expla-
nations behind the aneurysm formation of the graft.
The pioneering work by Sparks illustrated that the host
foreign body response could be tailored for in situ tissue en-
gineering purposes. Although aneurysm formation limited its
further clinical application, subsequent research groups aimed
to fine tune and reinvigorate this approach for the generation
of TEBV’s, by making use of the increasing knowledge of
biomaterials and the dynamics of the FBR.
This review will discuss vascular tissue engineering (VTE)
approaches that utilize the patient’s body as a bioreactor for
the development of completely autologous TEBV’s. The con-
text of these studies and their approach will be discussed.
Furthermore, the complex process of clinical translation of
and the use of appropriate animal models will be debated.
The Foreign Body Response
In order to understand how the host environment can contrib-
ute to the formation of new tissues in response to an implanted
biomaterial, it is important to understand the cells and path-
ways involved in the FBR. All biomaterials elicit a cellular
and tissue response when implanted in vivo, known as the
FBR [13, 26]. If a foreign body is small and superficial
enough it will be extruded from the body. If the foreign body
is too large to extrude, it will be encapsulated to ensure there is
a safe barrier between it and the host. Initially, the implanta-
tion of a biomaterial causes mechanical damage to the
vascularized connective tissue at the implant site. In this very
early process of the FBR, blood material interactions caused
by implantation result in the immediate adsorption of proteins
onto the surface of the implant creating what is known as the
provisional matrix [27].
The provisional matrix is composed of numerous bio-
reactive agents, including fibronectin, complement compo-
nents, albumin, and vitronectin. This makes it crucial in deter-
mining the activity, proliferation, migration, and differentia-
tion of inflammatory and wound healing cells [26]. Notably,
fibrinogen can absorb directly on the biomaterial surface, cre-
ating a dense fibrin network, which sequentially promotes
leukocyte adhesion [28, 29]. This presence of fibrinogen is
vital, as it has been shown that mice with depleted fibrinogen
were unable to initiate an inflammatory response to implanted
biomaterials [30]. Complement factors can spontaneously ad-
sorb to the biomaterial, which can lead to the activation of the
alternative complement pathway [31–33]. Due to the mechan-
ical nature of the formation of the provisional matrix, its com-
position can vary greatly depending on the implant location,
and surface properties of the implant [27]. Furthermore, vari-
ations in protein adsorption occur due to what is known as the
Vroman effect, which describes a competitive protein ex-
change on biomaterial surfaces, i.e. the competitive displace-
ment of adsorbed proteins by other proteins with stronger
binding affinities [34].
Following the formation of the provisional matrix, the ini-
tiation of the acute inflammatory response is the next phase of
the FBR, characterized by the infiltration of neutrophils. In
this phase the wound site is cleaned, vessels dilate and blood
flow to the injury site increases. A variety of cytokines and
growth factors are released, monocytes infiltrate the implan-
tation site and begin to differentiate to macrophages [26]. It
has been shown that histamine inhibition significantly de-
creased phagocyte recruitment, elucidating the importance of
mast cells and histamine in the acute FBR [35].
If the inflammatory stimulus persists, in case the biomate-
rial is not removed; the inflammatory response enters a chron-
ic phase. Normally, the acute phase lasts from several hours to
several days; chronic inflammation generally lasts no longer
than two weeks as long as the inflammatory stimulus does not
persist any longer [26]. Yet, the extent of damage that occurs
at the implant site is vital in determining the length and sever-
ity of the acute, and the chronic inflammatory phases. This
phase is characterized by monocyte infiltration, macrophage
activation and angiogenesis of the site of tissue injury [26].
Angiogenesis is essential to support the wound healing pro-
cess with a supply of nutrients. Following an early angiogenic
pulse caused by fibrin [36], histamine [37], and VEGF (re-
leased by platelets), the angiogenic process is later maintained
by hypoxic macrophages and fibroblasts in the new tissue
[38].
Monocyte and macrophage recruitment to the wound site is
driven by numerous chemoattractants such as IL-1β, IL-4,
TNF-a, and CCL2, which facilitate proliferation, and the ex-
travasation of leucocytes [39–41]. Macrophages have been
shown to initially secrete IL- β, and IL-6, and eventually
express more IL-10 as time progressed, indicating a pheno-
typic shift from a pro-, to an anti-inflammatory state [42]. If
the foreign body is too large to be phagocytize activated mac-
rophages fuse together to form multinucleated foreign body
giant cells (FBGC’s), a characteristic feature of chronic in-
flammation. Vitronectin, commonly present in the provisional
matrix has been shown to support macrophage adhesion, and
foreign body giant cell formation [43]. If the FBGC’s are
unable to remove the foreign body, the process of encapsula-
tion is initiated by surrounding the implant with a dense col-
lagen matrix [44]. Macrophages and FBGC’s stimulate fibro-
blasts to proliferate and overproduce components of the extra-
cellular matrix (ECM), including collagen, by releasing
TGF-β, IL-4, IL10, IL13, TNF-a, and IL-1 [45, 46]. It should
be noted that TGF-β is regarded as the most potent inducer of
the ECM formation [38]. Granulation tissue is characterized
by the immigration of fibroblasts, angiogenesis in the newly
developed tissue, and the presence of a layer of macrophages
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or FBGC’s lining the implant. If the stimulus is not resolved, a
thick fibrous capsule ultimately forms that is very rich in col-
lagen, (myo-) fibroblasts, and one or two layers macropaghes
and FBCG’s [26, 38]. It is proposed that if the inflammatory
stimulus remains for multiple months, the tissue becomes less
cellularized, ECM rich scar tissue as was seen in the Sparks’
graft. An overview of the FBR for biomaterials aimed at the
generation of in vivo autologous TEBV’s is provided in
Figure 2
Tailoring the FBR
The host FBR to an implant is a complex reaction, where host
features, implant characteristics, and implantation duration all
contribute to the response generated. However, in its complex-
ity it is clear that many factors can influence the host response
to a biomaterial. Regardless, the host environment and sur-
rounding tissue are an interesting cellular source for in vivo
tissue regeneration strategies [47, 48]. Since the application of
the Spark’s graft, much research has been done on the FBR
and how it could be modulated to provide a cellular source for
the construction of new tissue structures in vivo.
Firstly, biomaterial characteristics are critical in defining
the FBR response that is generated. The chemical composi-
tion, hydrophilicity, topography, and coating of the biomate-
rial can critically influence the initial cell-material interactions
that occur [49–51]. Therefore, by altering the composition of
the biomaterial the resulting foreign body response can be
modulated. For example, if the composition and adherence
of the provisional matrix is altered, it can impact the following
cellular reaction [52]. Moreover, macrophage adherence is
known to be essential in driving the FBR [26]. If a material
can alter macrophage adherence, this will also greatly influ-
ence the resulting FBR. For example, solvent etching and gas
plasma treatment is known to affect cell attachment to bioma-
terial surfaces [53, 54]. Secondly, the length of implantation
period is vital in determining the tissue structure that is devel-
oped. Very early in the foreign body response, the tissue will
be largely composed of neutrophils, have a highly inflamma-
tory profile, and low collagen content (and therefore poor
mechanical properties). Yet, a too long incubation step (sev-
eral months) will result in largely acellular tissue unable to
adequately remodel in the vasculature potentially leading to
aneurysm formation, as was seen in the Sparks graft. Thirdly,
implantation location is vital in determining the FBR to a
biomaterial. Fibroblasts differ at varying anatomical sites,
and with disease processes [55]. Moreover, fibroblasts from
separate tissues differ in their production of matrix metallo-
proteinases (MMP’s), the production of collagen, and prolif-
eration, meaning that the degree of encapsulation is likely to
vary between tissues [56].
Overview of Approaches for in Situ Vascular Tissue
Engineering
Since the application of the Sparks graft in the 1960’s, the
group of Campbell was the first to reconsider the utilization
of the body as a bioreactor for the generation of new tissue, by
using the peritoneal cavity as implant location. Themotivation
behind this approach is that besides showing a sufficient FBR
to the implanted material, mesothelial cells can be recruited to
the tissue capsule. Mesothelial cells and endothelial cells have
been shown to have various similarities, including a non-
thrombotic tendency [57].
In both rat and rabbit models, a piece of silastic (an inert
silicone elastomer) tubing was implanted in the peritoneal
cavity. Two weeks after implantation the implants were har-
vested and the silastic tubing removed from surrounding tis-
sue capsule. The resulting tissue capsule was covered by
layers of myofibroblast, and a single layer of mesothelial cells.
Next, the tissue capsules were reverted, so that the outer me-
sothelial layer of the capsule lined the lumen during grafting.
The tissue capsules were implanted as arterial interposition,
left in place for a maximum of 4 months. Ultimately, the
TEBV’s showed an overall patency of 67% in rats, and 70%
in rabbits. Prior to grafting, the granulation tissue was shown
to be rich in β-actin, and desmin indicating the contractile
capacity of the cells. However, low levels of smooth muscle
myosin heavy chain (a marker for smooth muscle cells
(SMC’s)) were observed in the capsules. One month after
implantation, arterial levels of myosin heavy chain were re-
ported, indicating a phenotypic shift of the myofibroblasts to a
SMC-like cell. Furthermore, 1 month after implantation the
presence of an internal elastic lamella was observed. The
TEBV was shown to respond positively when treated with
contractile and relaxing agents. However, only 50% of the
implants produced suitable TEBV’s, occasionally producing
no usable tissues in an animal, a notable limitation of this
method [58].
Subsequently, the approach was attempted in 15 mongrel
dogs, where various types of implant materials were assessed
for their suitability as TEBV. Some of the implants were fore-
seen of an external mesh. 3–3.5 mm in diameter TEBV’s were
implanted in either the peritoneal or pleural cavity for 3 weeks,
allowing the formation of tissue capsules around the implants,
and then grafted as arterial interposition in the femoral artery.
In this model the TEBV’s were not everted prior to grafting.
The mesh implants produced usable TEBV’s in all cases, yet
had a poorer patency of 60% between 3 and 6.5 months. Only
half of the implants without a mesh produced usable TEBV’s,
yet had a patency of 83% between 3 and 6.5 months. The
uncoated TEBV’s showed an impressive remodeling of its
cellular composition. Themyofibroblasts appeared to undergo
a phenotypic switch to SMC like cells, and endothelization of
the TEBV was observed as well. Furthermore, the TEBV had
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an adequate burst pressure of 2500 mmHg, allowing safe im-
plantation into the vasculature [59].
More recently, the method was improved by allowing the
TEBV’s to be generated under pulsatile conditions, signifi-
cantly improving the mechanical properties of the vessels.
The application of sheer stress has been shown to promote
ECM protein production [60].
Clearly, the group of Campbell had shown the potential of a
TEBV formed by the FBR within a host organism. A major
advantage of the technique being everting the TEBV’s to ex-
pose mesothelial cells before grafting, whereas the invasive
peritoneal implantation of the silastic tubing, comprises a rel-
ative disadvantage of this technique when compared to sub-
cutaneous approaches that are discussed below.
Following the example of the group of Peirce et al., who in
1953 attempted to make vessel constructs out of aortic colla-
gen, Tsukagoshi et al. attempted to create autologous TEBV’s
using subcutaneously implanted silicone surrounded by a lay-
er of fascia [61]. Amajor advantage of a subcutaneous implant
location is the rapid regenerative capacity of the skin [62],
which could lead to rapid development of tissue surrounding
an implant. Besides only a silicone implant, a biological com-
ponent from the host was added to the biomaterial in order to
reinforce the TEBV. A 10x40mm segment of fascia from the
dorsum and medial thigh of 15 rabbits was removed, wrapped
around silicone tubes, and implanted in subcutaneous pockets.
Four weeks later, the tubes were removed from the body and
the silicone tube was removed from the fibrous capsule com-
posed of fascia and a fibrocollagen mesh. The exposed
collagen promoted platelet adhesion and thrombus formation
[63]. A lumen composed entirely of collagen could therefore
be highly thrombogenic. It was then interposed into the fem-
oral artery of the rabbits as an end-to-end graft. Patency rates
of 80% were reported at 5 and 8 weeks, and re-
endothelialization of the TEBV was shown to occur. No an-
eurysm formation was reported, indicating that the method
provided adequate mechanical strength. However, intimal hy-
perplasia was reported at both ends of the TEBVof 70% of the
lumen, yet not in the center of the TEBV. This would indicate
an increased proliferation of cells near both anastomoses like-
ly as a result of the turbulent flow [16].
Another interesting approach has been developed by the
group of Nakayama, who aims to create TEBVwith a silicone
implant. They have termed the fibrous tissue capsule that
grows around their silicone implant ‘biotubes’. In their first
report of the biotube they reported well-formed grafts a burst-
ing pressure of at least 200mmHg [64]. Subcutaneous implan-
tation is advantageous due to the large population of dermal
fibroblasts, which could promote the formation of new tissue.
In their first grafting study in rabbits, an 82% patency rate
of the biotubes was reported at 12 weeks. Again, as the tissue
capsules are largely composed of myofibroblasts and colla-
gen. To reduce the risk of thrombosis, the potent anticoagulant
Argatroban was administered to the fibrous capsule prior to
grafting. Argatroban is commonly used in patients with hep-
arin induced thrombocytopenia (HIT) requiring an antithrom-
botic therapy [65]. The tissue capsule around the biotube was
composed of f ibroblasts , whereas af ter graf t ing
Fig. 2 An overview of the foreign body response. Following
implantation a provisional matrix immediately forms around the
implant. Following provisional matrix formation acute inflammation is
mainly characterized by the presence of neutrophil, and some monocyte
infiltration and differentiation. Chronic inflammation is characterized by
the infiltration of monocytes that differentiate to macrophages, and
neovascularization. Fibroblasts then proliferate and begin to produce
ECM components including collagen. A fibrous capsule forms
composed out of a (myo-)fibroblasts, ECM components (mainly
collagen), and a one- to two-layer of macrophages. Over time scar
tissue forms mainly composed of ECM and collagen, with less
fibroblasts. The optimal tissue composition for use as TEBV is a thick
cellularized fibrous capsule, which is collagen rich with relatively few
inflammatory cells
J. of Cardiovasc. Trans. Res.
circumferential collagen, myofibroblasts and possible SMC
were reported [66]. In a subsequent study, the TEBVremained
patent for an impressive 2 years in one animal, and showed
signs of both elastin formation and endothelialization [67].
The extremely limited sample size does fundamentally limit
the conclusions that can be drawn. The concept appeared to be
somewhat less successful in a rat model, where a patency of
67% at 12 weeks was reported. Again, elastin formation and
endothelialization of the TEBVwas reported. Several creative
improvements to stimulate tissue growth were implemented
on the implants, such as the addition of nicotine, optical stim-
ulation using LED’s, and the addition of eosin-Y, which were
all shown to stimulate fibrous capsule formation [68–70].
In a recent study the acute phase patency of a new biotube
type, designed around a silicone cage as appose to a plain rod,
was compared to the original silicone rod mediated biotube
design in 6 beagle dogs. Following a 4 week implantation in
the dorsal subcutaneous pocket, the silicone implant was re-
moved and the resulting tissue capsule was grafted into the
femoral artery. The new biotube design was shown to have a
burst pressure of 1825mmHg, compared to 944mmHg for the
original biotube [15]. At 7 days the acute patency was ob-
served by means of angiography. The new biotube design
had a 100% patency, compared to a patency of 33% for the
original biotube [15]. This research again underlines the po-
tential of the in vivo bioreactor approach.
Our group has also attempted to generate autologous grafts
in situ by focusing on the surface characteristics implanted
biomaterials. It is known that the surface characteristics of
an implanted biomaterial are key in driving the FBR and fi-
brous capsule formation [18, 51]. Ultimately, we aim to de-
velop a TEBV to be used as vascular access site for hemodi-
alysis. Our reasoning is that, due to the growing number of
patients requiring hemodialysis treatment and limited vascular
access options, TEBV’s could fundamentally improve this
huge clinical problem for hemodialysis patients.
In a study in 15 rats, various surface modifications of a few
materials were assessed in their effectiveness in propagating
an encapsulating response. These included gas plasma treat-
ments, collagen I and TGF-B coating, and chloroform etching.
While the thickest tissue capsules were produced using TGF-
B and collagen coating, this tissue was less uniform and had a
low cell density. It was shown that the copolymer poly(ethyl-
ene oxide terephthalate/polybutylene terephthalate)
(PEOT/PBT) which was chloroform etched provided the most
ideal tissue; providing a thick collagen layer with a high cell
density of circumferentially aligned myofibroblasts and initial
signs of elastin formation. It was shown that chloroform etch-
ing increased the surface roughness and oxygen content of the
polymer, resulting in an enhanced cell adhesion [51].
Sequentially, the method was assessed in a porcine model.
Chloroform etched rods were implanted subcutaneously in the
abdomen of 4 pigs. Four weeks later the polymer implants
were removed and two tissue capsules were implanted bilat-
erally as carotid interposition grafts. A 1 week patency of
100%, and 4 week patency of 88% was reported. Prior to
grafting, the tissue capsules were shown to be largely com-
posed of collagen, glycosaminoglycans, fibroblasts, and some
myofibroblasts. Directly lining the lumen leucocytes were ob-
served, with hardly any FBGC’s. After grafting an increase in
luminal diameter was shown, where the luminal side of the
tissue capsule was covered by a monolayer of endothelial
cells. The initial leucocytes lining the lumen was no longer
present, most likely due to hemodynamic factors. The remain-
ing cells in the tissue were mainly SMC like cells. The poten-
tial of modifying the surface characteristics of a biomaterial to
modulate the FBR after implantation was shown to be a viable
method of producing a cell rich TEBV. Clearly, the FBR can
be steered to generate tissues with for varying purposes, in-
cluding TEBV generation.
An overview of the animal studies carried out by the groups
discussed above, in which TEBV’s were grafted into the vas-
culature is provided in Table 2.
Remodeling of TEBV after Implantation
in the Circulation
Ideally, tissue engineered grafts mimic the composition of
native vessels. These are composed of a thin layer of healthy
endothelial cells, surrounded by layers of connective tissue,
SMC’s, and elastic laminae depending on the location, diam-
eter and function of the vessel. Grafts derived from fibrous
capsule formation tend to be rich in collagen, myofibroblasts,
and have one- to two-layers of macrophages directly sur-
rounding the implant. Remodeling in circulation is an essen-
tial step in the maturation of these in vivo grown grafts to
attain attributes that more accurately mimics native vessels.
A hallmark of a functional vessel is the presence of a
healthy endothelial monolayer, as this reduces the
thrombogenicity and promotes the homeostasis of a vessel
[72, 73]. A major struggle for all tissue engineering ap-
proaches is the incorporation of a functional endothelium that
can handle the arterial flow rates following a grafting proce-
dure and remain in place long term [74]. Numerous attempts
have been made to seed endothelial cells on both TEBV’s and
vascular grafts prior to grafting, however this has proven to be
deceptively complex [75]. Exposed collagen on the lumen of
in vivo grafts provide a potentially thrombogenic surface
shortly after insertion in the circulation. Campbell et al. al-
ready showed an elegant approach to this problem by lining
the luminal side of the TEBV with autologous mesothelial
cells [58]. Despite the difficulty of seeding an endothelium
upon TEBV’s prior to grafting, all studies using the in vivo
grafts have shown endothelialization of the lumen [14, 16, 59,
71]. Although, the function of endothelial progenitor cells is
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decreased in patients with chronic kidney disease [76].
Spontaneous endothelialization of decellularized TEBV’s
has recently been demonstrated in ESRD patients [77]. It re-
mains to be determined whether this endothelialization of the
grafts results from circulating EPCs that adhere to the surface
of the TEBV, or result from the migration of endothelial cells
from neighboring vessels to the graft.
Tissues grown as a result of the FBR are rich in fibroblasts
and myofibroblasts, but not SMC’s. SMC’s are important in
maintaining vascular homeostasis notably with regard to the
vasoreactivity of vessels. Various studies have shown that af-
ter grafting, populations of (myo-)fibroblasts have either
transdifferentiated to, of been replaced by SMC like cells
[14, 58, 59, 66]. A histological overview of the differentiation
of the tissue capsules towards blood vessel-like structures that
we observed in our pig studies is provided in Figure 3.
Moreover, Campbell et al. had reported an increased vasoac-
tivity of the grafts after being implanted for several months
[58, 59].
The structural integrity of a vessel is largely determined by
the ECM, and is able to fundamentally modulate various as-
pects of cell biology in addition to its structural role [78, 79].
Here, collagen is the determining factor of the strength of the
vessel [80]. Prior to grafting, TEBV’s that have grown as a
result of a FBR will have a different ECM as well as cellular
composition than native arteries. A breakdown of the ECM
could therefore lead to diminished mechanical properties of
the graft, and even aneurysm formation as was frequently seen
in the Spark’s graft [20]. In circulation, collagen, which ac-
counts for the mechanical strength of the ECM, can be broken
down by matrix metalloproteases (MMP’s), in particular
MMP-2 and MMP-9 [78]. This underlines the importance of
a cellularized graft, which could allow the production of ECM
components in vivo after it has been grafted into the
circulation.
Another important component of the vessel wall is elastin,
which is essential for vascular compliance [81]. Native elastin
is immensely durable with a half-life of approximately
70 years [82], and relatively resistant to chemical and biolog-
ical degradation [83, 84]. Thus far, the incorporation of elastin
into TEBV’s which can remain functional for a long time,
appeared to be extremely challenging [85, 86]. As elastin syn-
thesis only rarely occurs in adult life, the incorporation of
exogenous elastin fibers into the tissue might favor methods
that depend on in vivo synthesis of elastin [85, 86]. Ideally,
cells within the in vivo TEBV could remodel and begin to
produce elastin after grafting, although the process by which
this occurs in this the setting of FBR mediated TEBV’s is not
entirely understood. Nayakama et al. for example, had report-
ed the presence of elastin after grafting of the biotubes [71].
However, it remains to be demonstrated if functional elastic
fibers are formed which have a positive impact on vessel com-
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be an attractive method for elastogensis, with a superior
elastogenic potential when compared to IGF-1, TGF-β1, and
minoxidil [87].
Advantages and Disadvantages of in Situ Vascular
Tissue Engineering
There are clear advantages to using the host environment as an
in vivo bioreactor. Grafts are composed of entirely autologous
tissue, meaning no immunological mismatch is possible and
no prior infection is present. The approaches to creating an
in vivo TEBV require relatively simple polymer implants as
opposed to any type of in vitro fabricated vascular construct.
This means that this method has the potential of being cost
effective and widely available.
Clear disadvantages of this method of course also exist.
The grafts are limited in their applicability for acute proce-
dures, due to their biological incubation time that generally
requires several weeks. When utilizing in situ engineered
blood vessels, the length required for certain arterial bypass
procedures may not be attainable. For instance, creating
femoral-popliteal bypass grafts that cross the knee joint could
be challenging, as this requires flexible implant material to
allow bending during the growth of the TEBV. The state of
the host environment can alter the response to an implant.
Gender [88], age, and the presence of disease can alter the
response to an implant, and therefore the composition of the
generated tissue. End-stage renal failure can impact wound
healing and impair bone marrow function [76, 89].
Therefore the applicability of the grafts in these patient popu-
lations must be assessed in detail. As seen in some of the
methods discussed in this review, there is a potentially large
biological variation that must be assessed and controlled be-
fore these techniques can be considered for clinical
translation.
Animal Models
Ideally, an animal model is cheap, quickly develops a desired
pathology, is readily available and mimics vascular setting of
humans as closely as possible (i.e. thrombogenicity, vessel
size, immune response). Clearly no animal model exists that
fulfills all these requirements. In the development of a medical
device and its translation to the clinic, animal models are in-
dispensable. However, due to fundamental differences in the
molecular pathways and pathologies between animal models
and humans, animal studies do not translate well to the clinical
phases of development [90].
For studying molecular pathways, mice are an ideal model,
due to the large number of research tools and knockout ani-
mals available. However their small size makes vascular
grafting studies suboptimal. The slightly larger size of rats
and rabbits make these more suitable for early proof of con-
cept studies. Limitations here are the poor translation to the
clinic, as well as the relative lack of knock-out animals com-
pared to mice.
The vessels of larger animals are more representative of
humans and are more appropriate to mimic human vascular
conditions, as the size of the vasculature is determinant for the
sheer stress exacted on the vessel wall. Numerous sheep and
goat models have been described in vascular studies [91–93].
However, high variability in response to anticoagulant and
antiplatelet therapy in these animals is known to occur and
must be taken into account [94]. Dogs have comparable vas-
culature to humans, are easy to handle due to their familiarity
with humans, and readily available. Yet, dogs have however
been found to be hypercoagulant in an ex vivo analysis [95].
However, synthetic grafts have shown high patency rates in
dogs, with little sign of intimal hyperplasia, raising the ques-
tion if dogs are a stringent enough model for vascular appli-
cations [96]. The vasculature of non-human primates is most
similar to humans, making it the most accurate animal model
available. However, due to high costs, special housing
Fig. 3 Adapted from Rothuizen et al. Showing an autologous tissue
engineered blood vessel before, and after grafting. Before grafting α-
SMA, vimentin positive (myo-)fibroblasts are present, with frequent
CD-45 positive leucocytes and no endothelium (lectin negativity). After
grafting the cells are α-SMA, desmin positive SMC like cells with no
CD-45 positive cells and an endothelial monolayer [14]
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requirements, and stringent ethical concerns, the use of this
model is limited.
Arguably, the ‘aggressiveness’ of the vasculature is the
most important factor in assessing the long-term patency of
vascular grafts, with intimal hyperplasia being the most com-
mon cause of TEBV failure. Different animal models vary
greatly in the speed at which they develop intimal hyperplasia
[97]. One of the most commonly used models in cardiovascu-
lar research today is the pig model [97]. The responsive nature
of the vasculature of the pig makes it ideal for short-term
pathophysiology studies. However, it is known that pigs for
develop stenotic lesions up to six times faster than humans
[98], making them less appropriate, arguably too stringent,
for long term patency studies.
Clinical Perspective
There are factors to take into account in the translation of
TEBV methods to a clinical setting. Firstly, a TEBV derived
from the FBR would require an additional implantation pro-
cedure, besides the grafting of the TEBV into the vasculature.
Aside from this additional intervention, the use of these
TEBV’s may be somewhat surgically challenging, as the
TEBV must first be removed from the implant before it can
be grafted to the vasculature. The procedure would therefore
require additional training by a surgeon to carry out properly.
Following a surgical intervention, such as the implantation of
a medical device, a patient may be given immune suppres-
sants. Immune suppression may intervene with the FBR, and
therefore TEBV development, which would need to be
accounted for when considering FBR based TEBV methods
in a clinical setting. Before a FBR mediated TEBV method is
to be considered for a clinical setting, the variation between
patients must be well known, and accounted for, to assure all
TEBV’s meet all requirements set for vascular grafts. It is
known that for example CKD [89] and diabetes [99] can im-
pair wound healing. Therefore it is vital to show that the for-
mation of the TEBV’s in these patient populations occurs as
expected, and with acceptable variation between patients.
In a pioneering clinical trial, the group of Shinoka success-
fully employed TEBV’s, designed from bone marrowmononu-
clear cells, with no graft related mortality, indicating the poten-
tial of TEBV’s in a clinical setting [100]. In a more recent
clinical trial, the group of Niklason employed human acellular
vessels as vascular access in 60 patients with ESRD, showing a
primary patency of 28%, and secondary patency of 89% at
12 months post implantation, underlining the potential of
TEBV approaches as potential vessel replacement [77]. VA
sites offer an interesting target for the clinical implementation
of TEBV’s. The occlusion of an arterial bypass is potentially
fatal, while the occlusion of an arteriovenous conduit may ren-
der the VA site unusable, but is less dangerous for the patient,
minimizing the risk of the trial. As was also stated earlier, the
current options for creating a functioning arteriovenous graft
are poor. Implementing a TEBV as an arteriovenous graft can
be seen as a stringent model to assess TEBV functionality and
patency, due to the harsh hemodynamic conditions, and fre-
quent stenosis seen in arteriovenous conduits. Until now no
FBR mediated TEBVapproach has been assessed in a clinical
phase. Our group is expecting to initiate the first clinical phase
of our FBR mediated TEBV’s as VA before 2018.
Conclusion and Future Perspectives
In this review we have illustrated and summarized the poten-
tial of a body as a bioreactor for the generation of autologous
tissue engineered blood vessels in vivo, including the mecha-
nisms of the foreign body response that can result in new
tissues, research groups that have attempted to utilize this
approach, and the difficulties and limitations of developing
suchmethods. The potential of autologous in vivomade grafts
is clear through the promising pre-clinical studies that have
been carried out. With a continued understanding of the FBR,
and the common factors leading to graft failure, we foresee
more fine-tuned approaches to the generation of TEBV’s will
be assessed. The limitation of the approach has been elucidat-
ed, and must be overcome for the methods to ultimately be
successful. The translation of not only these, but all vascular
tissue engineering approaches remains difficult, and suitable
animals models must be chosen to allow for successful clinical
translation. In conclusion, autologous in vivo TEBV’s show
great potential as cell rich vascular grafts capable of remodel-
ing in the vasculature.
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